

*Co-Authors:* Hans C. Lee, Department of Lymphoma and Myeloma, M.D. Anderson Cancer Center, Houston, TX; Jiří Minařík, University Hospital Olomouc, Olomouc, Czech Republic; Jan Straub, First Medical Department–Clinical Department of Hematology of the First Faculty of Medicine, General Teaching Hospital, Prague, Czech Republic; Luděk Pour, Hematology, University Hospital, Brno, Czech Republic; Alexandra Jungova, Faculty Hospital Pilsen, Pilsen, Czech Republic; Jesus G. Berdeja, Sarah Cannon Center For Blood Cancers, Nashville, TN; Mario Boccardo, Division of Hematology, University of Torino, Italy; Lucie Brozova, Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Andrew Spencer, Department of Clinical Haematology, Alfred Health-Monash University, Melbourne, Australia; Frits Van Rhee, UAMS Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR; Jorge Vela-Ojeda, UMAE Especialidades Centro Medico La Raza IMSS, México, Mexico; Michael A. Thompson, Aurora Cancer Care, Aurora Research Institute, Advocate Aurora Health, Milwaukee, WI; Rafat Abonour, Hematology/Oncology, Indiana University School of Medicine, Indianapolis, IN; Ajai Chari, Icahn School of Medicine at Mount Sinai, New York, NY; Gordon Cook, Department of Haematology, Clinical Trials Research Unit, NIHR (Leeds) IVD Cooperative, Leeds Teaching Hospital, Leeds, United Kingdom; Caitlin L. Costello, Department of Medicine, Division of Blood and Marrow Transplantation, Moores Cancer Center, University of California San Diego, La Jolla, CA; Faith E. Davies, Perlmutter Cancer Center, NYU Langone, New York, NY; Vania T.M. Hungria, Department of Hematology, Clinica São Germano and Santa Casa Medical School, São Paulo, Brazil; Xavier Leleu, Pôle Régional de Cancérologie, CHU de Poitiers, Poitiers, France; Noemi Puig, Hospital Universitario de Salamanca Hematología. Instituto de investigación biomédica de Salamanca (IBSAL), Salamanca, Spain; Robert M. Rifkin, Hematology Research, US Oncology Research, Rocky Mountain Cancer Centers, Yampa Valley Medical Center, TX; Evangelos Terpos, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece; Saad Z. Usmani, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, NC; Katja C. Weisel, Department of Oncology, Hematology, Stem Cell Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Jeffrey A. Zonder, Department of Malignant Hematology, Barbara Ann Karmanos Cancer Institute/Wayne State University School of Medicine, Detroit, MI; Magda Barinova, Institute of Biostatistics and Analyses, Brno, Czech Republic; Matyas Kuhn, Institute of Biostatistics and Analyses, Brno, Czech Republic; Jiri Silar, Institute of Biostatistics and Analyses, Brno, Czech Republic; Lenka Capkova, Institute of Biostatistics and Analyses, Brno, Czech Republic; Kenny Galvez, Hospital Pablo Tobón Uribe, Medellín, Colombia; Jin Lu, Peking University People’s Hospital, National Clinical Research Center for Hematologic Disease, Beijing, China; Tomas Skacel, Millennium, a wholly owned subsidiary of Takeda, Cambridge, MA, and 1st Department of Medicine, First Faculty of Medicine, Charles University and General Hospital in Prague, Prague, Czech Republic; Jennifer Elliott, Millennium, a wholly owned subsidiary of Takeda, Cambridge, MA; Dawn Marie Stull, Millennium, a wholly owned subsidiary of Takeda, Cambridge, MA; Kaili Ren, Millennium, a wholly owned subsidiary of Takeda, Cambridge, MA; Vladimír Maisnar, 4th Department of Medicine-Haematology, Charles University Faculty Hospital, Hradec Králové, Czech Republic; Roman Hájek, Department of Hemato-oncology, University Hospital Ostrava, and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic